Cargando…

A target of potential RELAvance in inflammatory breast cancer

Detalles Bibliográficos
Autores principales:	Eckhardt, Bedrich L., Ueno, Naoto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432219/ https://www.ncbi.nlm.nih.gov/pubmed/28460487 http://dx.doi.org/10.18632/oncotarget.17109

Ejemplares similares

Cis-Cardio: A comprehensive analysis platform for cardiovascular-relavant cis-regulation in human and mouse
por: Song, Chao, et al.
Publicado: (2023)

Clinical evaluation of accommodation and ocular surface stability relavant to visual asthenopia with 3D displays
por: Wee, Sung wook, et al.
Publicado: (2014)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies
por: Eckhardt, Bedrich L., et al.
Publicado: (2018)

EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer
por: Wang, Xiaoping, et al.
Publicado: (2017)

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
por: Torres-Adorno, Angie M., et al.
Publicado: (2018)

CDK8: a new breast cancer target
por: Crown, John
Publicado: (2017)

Targeting Signaling Pathways in Inflammatory Breast Cancer
por: Wang, Xiaoping, et al.
Publicado: (2020)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research
por: Espinosa Fernandez, Jose Rodrigo, et al.
Publicado: (2020)

Allelic imbalance in human breast cancer
por: French, Juliet D., et al.
Publicado: (2017)

RUNX1 and breast cancer
por: Mercado-Matos, Jose, et al.
Publicado: (2017)

Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma
por: Patrone, Christina Chung, et al.
Publicado: (2019)

αTAT1: a potential therapeutic target in cancer?
por: Chien, J-Y, et al.
Publicado: (2016)

MiRNAs prognostic for basal and BRCA1 breast cancer
por: Pal, Bhupinder, et al.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Dissecting genetic risk factors in breast cancer
por: Harro, Carly M., et al.
Publicado: (2017)

Bispecific protein targets prostate cancer
por: Burgess, Antony W.
Publicado: (2017)

RUNX1, a new regulator of EMT in breast cancer
por: Khawaled, Saleh, et al.
Publicado: (2017)

CD9: A possible clue into breast cancer chemoresistance
por: Pacienza, Natalia, et al.
Publicado: (2019)

Targeting CRAC channels in inflammatory bowel disease
por: Kappel, Sven, et al.
Publicado: (2022)

Update on systemic treatment for newly diagnosed inflammatory breast cancer
por: Chainitikun, Sudpreeda, et al.
Publicado: (2020)

Cadmium and Breast Cancer: Exposure Associated with Basal-Like Phenotype
por: Barrett, Julia R.
Publicado: (2009)

LIGHT POLLUTION: Light at Night and Breast Cancer Risk Worldwide
por: Spivey, Angela
Publicado: (2010)

DVL regulation of tissue-specific aromatase transcripts in breast cancer
por: O’Hagan, Heather M.
Publicado: (2018)

Why isn’t the angiotensin type 1 receptor a target in cancer?
por: Vinson, Gavin P.
Publicado: (2017)

Survivorship and Advocacy in Inflammatory Breast Cancer
por: Alexander, Angela, et al.
Publicado: (2018)

Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
por: Braams, Esmée, et al.
Publicado: (2018)

Priorities for Breast Cancer Research: Taking Stock of Chemicals, Biomarkers, and Exposure Assessment Tools
por: Averett, Nancy
Publicado: (2014)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

Environment-Breast Cancer Link and Community Outreach Targeted
Publicado: (1994)

Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target
por: Richard, François, et al.
Publicado: (2023)

A novel immune regulator links malaria and inflammatory bowel disease
por: Sack, Brandon K., et al.
Publicado: (2014)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer
por: Antonarakis, Emmanuel S.
Publicado: (2018)

Targeting conformational changes in C‐reactive protein to inhibit pro‐inflammatory actions
por: Filep, János G
Publicado: (2022)

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review
por: Chainitikun, Sudpreeda, et al.
Publicado: (2021)

A potential novel option for cancer immunotherapy – TLR7 stimulation inhibits malignant melanoma bone invasion
por: Katagiri, Takenobu
Publicado: (2018)

Cancer and the arts: how often do doctors only see what they want to see? Or: the case of an ‘epidemic of breast cancer among famous artists’
por: Wagner, Wolfgang
Publicado: (2017)

From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science
por: Yu, Jau-Song
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_52si0im3g81k1mjj6iusr5ntp0